Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00278928 · ClinicalTrials.gov registry record · NA
Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 82
- Enrollment target
NCT00278928 is a NA study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 82 participants.
The verdict
NCT00278928, a NA study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 82 participants
- Enrollment target
Study Summary
This will be a prospective, randomized trial to determine if differences exist in the tolerance of lipid injectable emulsions in the neonatal intensive care unit (NICU). Lipid injectable emulsions are an essential nutrient for neonatal growth and development. Traditionally, lipid injectable emulsions have been commercially available in sterile glass bottles, but in April of 2004, a new container was introduced as a sterile plastic bag. In January, 2005, NICU personnel observed what appeared to be a higher than usual incidence of hypertriglyceridemia. Upon further laboratory investigation of the lipid injectable emulsions stored in glass bottles versus those in plastic, significant differences were noted in the population of large-diameter fat globules by globule size analysis, reflective of a less stable emulsion in plastic. The United States Pharmacopeia (USP) which sets the standards for drug purity and safety in the U.S., and whose drug monographs are enforceable by the FDA, has proposed to limit this large diameter fat globule population to a volume-weighted percent fat greater than five micrometers or PFAT5 to be less than 0.05% of the total lipid concentration. (At the present time, the USP monograph is not officially recognized, but is on track for adoption in 2006.) Our preliminary analyses of four lots of 20% lipid injectable emulsion packaged in glass to have a PFAT5 of 0.003±0.0008%, compared to an approximate 55-fold increase in the large-diameter fat globule population or 0.166±0.016% for an equal number of products packaged in plastic. We hypothesize this difference may explain the recent clinical observations. We will compare the incidence of hypertriglyceridemia in neonates between lipids packaged in glass versus those in plastic. The study will attempt to discern whether the differences in packaging influence the stability and subsequent tolerance of lipid injectable emulsions.
Interventions
- DRUG Liposyn III 20% (lipid infusion)
- DRUG Intralipid 20% (lipid infusion)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00278928
The ClinicalTrials.gov registry entry for NCT00278928 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposyn III 20% (lipid infusion) is the first listed.
NCT00278928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00278928 about?
NCT00278928 is a clinical study titled "Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic". This will be a prospective, randomized trial to determine if differences exist in the tolerance of lipid injectable emulsions in the neonatal intensive care unit (NICU). Lipid injectable emulsions are an essential nutrient for neonatal growth and development. Traditionally, lipid injectable emulsion...
What is the current status of trial NCT00278928?
This trial is currently terminated. It is a NA study. The enrollment target is 82 participants. The study started on 2006-01. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00278928?
The interventions under investigation include: Liposyn III 20% (lipid infusion) (DRUG), Intralipid 20% (lipid infusion) (DRUG).
Who is sponsoring clinical trial NCT00278928?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.